Feedback / Questions
Sotyktu (deucravacitinib) - BMS
Results from the OLE of the POETYK PsA-1 study will also be presented at an upcoming medical meeting.
(Bristol-Myers Squibb Press Release)
Sep 17, 2026
P3 data
•
Immunology • Psoriatic Arthritis
https://news.bms.com/news/corporate-financial/2026/Bristol-Myers-Squibb-Presents-Sotyktu-deucravacitinib-Data-Showing-Durable-Efficacy-Consistent-Safety-in-Adults-with-Psoriatic-Arthritis-Over-Two-Years/default.aspx
Sep 17, 2026
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next